Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382079 | 0.95 | KMT2A (0.58) | KMT2AUSP2AKR1C3ALDH1A1L3MBTL1 | |
| SCHEMBL2703274 | 0.92 | ALDH1A1 (0.58) | KMT2AUSP2AKR1C3ALDH1A1L3MBTL1 | |
| SCHEMBL539280 | 0.92 | ALDH1A1 (0.58) | KMT2AUSP2AKR1C3ALDH1A1L3MBTL1 | |
| SCHEMBL10401247 | 0.92 | KMT2A (0.56) | KMT2AUSP2AKR1C3ALDH1A1L3MBTL1 | |
| SCHEMBL31252540 | 0.89 | AKR1C3 (0.57) | KMT2AUSP2AKR1C3ALDH1A1MAPT | |
| Methyl Alcohol SCHEMBL10664077 | 0.88 | KMT2A (0.57) | KMT2AUSP2AKR1C3ALDH1A1L3MBTL1 | |
| SCHEMBL28356161 | 0.86 | ALDH1A1 (0.59) | KMT2AUSP2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL24596933 | 0.85 | CHKA (0.62) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL29173466 | 0.83 | AKR1C3 (0.57) | KMT2AUSP2AKR1C3ALDH1A1MAPT | |
| SCHEMBL2095208 | 0.81 | KMT2A (0.44) | KMT2AUSP2AKR1C3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230121497-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4096668-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021155264-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155264-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | KMT2A 1159/4885USP2 252/4885AKR1C3 4344/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | KMT2A 1159/4885USP2 252/4885AKR1C3 4344/4885 |
| US-20230121497-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | KMT2A 792/4885USP2 2391/4885AKR1C3 3263/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | KMT2A 1159/4885USP2 252/4885AKR1C3 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.